Skip to main content

Phase 1 Start

ATTO: Phase1_Start: A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

December 14, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
December 14, 2026
Company
Attovia Therapeutics, Inc. (ATTO)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 1 Start

Phase1_Start: A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis

ATTO overview →

Other upcoming events for ATTO

Phase 2 StartPhase2_Start: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ATTO-1310 for the Treatment of Participants With Chronic Pruritus of Unknown Origin